Drugs / 68Ga-DOTA-JR11
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04689893 | Mar 2020 → Mar 2021 | Oncogenic osteomalacia | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-DOTA-JR11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04689893 ↗ |
| Action | Inhibit | “68Ga-DOTA-JR11 is a SSTR2 specific antagonist used for PET tracer.” NCT04689893 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-DOTA-JR11 is a SSTR2 specific antagonist used for PET tracer.” NCT04689893 ↗ |
| Route | Subcutaneous | “The patients were subcutaneously injected with 68Ga-DOTA-TATE and 68Ga-DOTA-JR11 and underwent PET/CT scan 20\~40min after the injection in two consecutive days.” NCT04689893 ↗ |
| Target | SSTR2 | “68Ga-DOTA-JR11 is a SSTR2 specific antagonist used for PET tracer.” NCT04689893 ↗ |